Atazanavir NEW

Price	$5	$0.1
Package	1KG	1000KG

Min. Order:	1KG
Supply Ability:	g-kg-tons, free sample is available
Update Time:	2024-04-16

Product Details

Product Name: Atazanavir	CAS No.: 198904-31-3
Min. Order: 1KG	Purity: 99%
Supply Ability: g-kg-tons, free sample is available	Release date: 2024/04/16
Lead time: In stock, ready for shipment	Packaging: bag/bottle/drum/IBC
Delivery: By express, by air, by sea	Origin: Manufacturer, advantage product
COA, MSDS: Available, contact us for details	Name: Tina

1. Materials information

Name	atazanavir
Synonym	More Synonyms

Description	Atazanavir(BMS-232632) is an highly potent HIV-1 protease inhibitor.IC50 value:Target: HIV-1 protease inhibitorAtazanavir sulfate is a sulfate salt form of atazanavir that is an highly potent HIV-1 protease inhibitor. It has a pharmacokinetic profile that supports once-daily dosing and has demonstrated a unique resistance profile and superior virologic potency compared with other antiretrovirals in vitro. In subjects with HIV, atazanavir (400 mg once daily) produced rapid and sustained improvements in viral load and CD4 counts in both antiretroviral-naive as well as previously treated patients when used in combination with dual nucleoside reverse transcriptase inhibitor (NRTI) treatment [1].After intravenous (iv), oral (po) and intraportal (ip) administration of ATV at a dosage of 7 mg/kg, AUCs in HL rats were 12.41, 5.24 and 8.89 microg/mLh, respectively, and were significantly higher than those in control rats (4.09, 1.70 and 3.38 microg/mLh). Despite the decrease of distribution volume (Vd(ss)), the terminal half-life (t(1/2)) in HL tended to be shorter than in control, and hepatic distribution of ATV in HL rats was 4.8-fold increases. These results suggested that the uptake of ATV into liver might counteract the decrease of Vd(ss). On the other hand, there was no significant difference in bioavailability, and the lymphatic transport to AUC showed no statistical change. In conclusion, although the protein binding rate and AUC were significantly increased, the pharmacokinetics of ATV might be tolerated in HL [2].Clinical indications: HIV-1 infection Toxicity: torsades de pointes
Related Catalog	Signaling Pathways >> Metabolic Enzyme/Protease >> HIV Protease Signaling Pathways >> Anti-infection >> HIV Research Areas >> Infection
References	[1]. Gianotti N, Soria A, Lazzarin A. Antiviral activity and clinical efficacy of atazanavir in HIV-1-infected patients: a review. New Microbiol. 2007 Apr;30(2):79-88. [2]. von Hentig N. Atazanavir/ritonavir: a review of its use in HIV therapy. Drugs Today (Barc). 2008 Feb;44(2):103-32. [3]. Wood R. Atazanavir: its role in HIV treatment. Expert Rev Anti Infect Ther. 2008 Dec;6(6):785-96. [4]. Croom KF, Dhillon S, Keam SJ. Atazanavir: a review of its use in the management of HIV-1 infection. Drugs. 2009 May 29;69(8):1107-40. [5]. Bentué-Ferrer D, Arvieux C, Tribut O et al. Clinical pharmacology, efficacy and safety of atazanavir: a review. Expert Opin Drug Metab Toxicol. 2009 Nov;5(11):1455-68. [6]. Atazanavir

Description

Atazanavir(BMS-232632) is an highly potent HIV-1 protease inhibitor.IC50 value:Target: HIV-1 protease inhibitorAtazanavir sulfate is a sulfate salt form of atazanavir that is an highly potent HIV-1 protease inhibitor. It has a pharmacokinetic profile that supports once-daily dosing and has demonstrated a unique resistance profile and superior virologic potency compared with other antiretrovirals in vitro. In subjects with HIV, atazanavir (400 mg once daily) produced rapid and sustained improvements in viral load and CD4 counts in both antiretroviral-naive as well as previously treated patients when used in combination with dual nucleoside reverse transcriptase inhibitor (NRTI) treatment [1].After intravenous (iv), oral (po) and intraportal (ip) administration of ATV at a dosage of 7 mg/kg, AUCs in HL rats were 12.41, 5.24 and 8.89 microg/mLh, respectively, and were significantly higher than those in control rats (4.09, 1.70 and 3.38 microg/mLh). Despite the decrease of distribution volume (Vd(ss)), the terminal half-life (t(1/2)) in HL tended to be shorter than in control, and hepatic distribution of ATV in HL rats was 4.8-fold increases. These results suggested that the uptake of ATV into liver might counteract the decrease of Vd(ss). On the other hand, there was no significant difference in bioavailability, and the lymphatic transport to AUC showed no statistical change. In conclusion, although the protein binding rate and AUC were significantly increased, the pharmacokinetics of ATV might be tolerated in HL [2].Clinical indications: HIV-1 infection Toxicity: torsades de pointes

Related Catalog

Signaling Pathways >> Metabolic Enzyme/Protease >> HIV Protease

Signaling Pathways >> Anti-infection >> HIV

Research Areas >> Infection

References

[1]. Gianotti N, Soria A, Lazzarin A. Antiviral activity and clinical efficacy of atazanavir in HIV-1-infected patients: a review. New Microbiol. 2007 Apr;30(2):79-88.

[2]. von Hentig N. Atazanavir/ritonavir: a review of its use in HIV therapy. Drugs Today (Barc). 2008 Feb;44(2):103-32.

[3]. Wood R. Atazanavir: its role in HIV treatment. Expert Rev Anti Infect Ther. 2008 Dec;6(6):785-96.

[4]. Croom KF, Dhillon S, Keam SJ. Atazanavir: a review of its use in the management of HIV-1 infection. Drugs. 2009 May 29;69(8):1107-40.

[5]. Bentué-Ferrer D, Arvieux C, Tribut O et al. Clinical pharmacology, efficacy and safety of atazanavir: a review. Expert Opin Drug Metab Toxicol. 2009 Nov;5(11):1455-68.

[6]. Atazanavir

Density	1.2±0.1 g/cm3
Melting Point	207-209ºC
Molecular Formula	C38H52N6O7
Molecular Weight	704.856
Exact Mass	704.389771
PSA	171.22000
LogP	5.20
Index of Refraction	1.562

Hazard Codes	Xi

4-(2-Pyridinyl)...

127406-56-8

Atazanavir

198904-31-3

Literature: Journal of Medicinal Chemistry, , vol. 41, # 18 p. 3387 - 3401

2-Bromopyridine

109-04-6

Atazanavir

198904-31-3

Literature: Journal of Medicinal Chemistry, , vol. 41, # 18 p. 3387 - 3401

4-Bromobenzalde...

24856-58-4

Atazanavir

198904-31-3

Literature: Journal of Medicinal Chemistry, , vol. 41, # 18 p. 3387 - 3401

Precursor 8	Previous 1/2 Next
CAS#:857904-02-0 L-Valine, N-(me... CAS#:79-22-1 Methyl chloroformate CAS#:127406-56-8 4-(2-Pyridinyl)... CAS#:109-04-6 2-Bromopyridine
DownStream 0

methyl N-[(2S)-1-[2-[(2S,3S)-2-hydroxy-3-[[(2S)-2-(methoxycarbonylamino)-3,3-dimethylbutanoyl]amino]-4-phenylbutyl]-2-[(4-pyridin-2-ylphenyl)methyl]hydrazinyl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate

Zrivada

Methyl {(5S,10S,11S,14S)-11-benzyl-5-tert-butyl-10-hydroxy-15,15-dimethyl-3,6,13-trioxo-8-[4-(pyridin-2-yl)benzyl]-2-oxa-4,7,8,12-tetraazahexadecan-14-yl}carbamate

Atazanavir

BMS-232632-05

2aqu

[3H]-Atazanavir

(3S,8S,9S,12S)-3,12-Bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-((4-(2-pyridinyl)phenyl)methyl)-2,5,6,10,13-pentaazatetradecanedioic acid Dimethyl Ester

Methyl-{(5S,10S,11S,14S)-11-benzyl-5-tert-butyl-10-hydroxy-15,15-dimethyl-3,6,13-trioxo-8-[4-(pyridin-2-yl)benzyl]-2-oxa-4,7,8,12-tetraazahexadecan-14-yl}carbamat

(3S-(3R*,8R*,9R*,12R*))-3,12-Bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-((4-(2-pyridinyl)phenyl)methyl)-2,5,6,10,13-pentaazatetradecanedioic acid Dimethyl Ester

butanoic acid, 2-[(methoxycarbonyl)amino]-3,3-dimethyl-, 2-[(2S,3S)-2-hydroxy-3-[[(2S)-2-[(methoxycarbonyl)amino]-3,3-dimethyl-1-oxobutyl]amino]-4-phenylbutyl]-2-[[4-(2-pyridinyl)phenyl]methyl]hydrazi

Methyl {(5S,10S,11S,14S)-11-benzyl-10-hydroxy-15,15-dimethyl-5-(2-methyl-2-propanyl)-3,6,13-trioxo-8-[4-(2-pyridinyl)benzyl]-2-oxa-4,7,8,12-tetraazahexadecan-14-yl}carbamate

Reyataz

Butanoic acid, 2-[(methoxycarbonyl)amino]-3,3-dimethyl-, 2-[(2S,3S)-2-hydroxy-3-[[(2S)-2-[(methoxycarbonyl)amino]-3,3-dimethyl-1-oxobutyl]amino]-4-phenylbutyl]-2-[[4-(2-pyridinyl)phenyl]methyl]hydrazide, (2S)-

Methyl {(5S,10S,11S,14S)-11-benzyl-5-tert-butyl-10-hydroxy-15,15-dimethyl-3,6,13-trioxo-8-[4-(pyridin-2-yl)benzyl]-2-oxa-4,7,8,12-tetraazahexadecan-14-yl}carbamate (non-preferred name)

UNII-QZU4H47A3S

2. Packaging of materials

For powders: normal is 25kgs/Drum or bag, or larger/smaller package as request.
For liquids: normal 25kgs/drum, 180-300kgs/bucket, or IBC, determined by the nature of the product.

Or smaller package 1kg/bottle, 10kgs/bottle as request.

Article illustration

3. Shipping & Delivery

By Express

Provide door to door service

Suitable for goods under 50kg

Delivery: 3-7 days

Cost: low cost

Article illustration

By Air

Provide airport to airport service

Suitable for goods over 50kg

Delivery: 3-14 days

Cost: high cost

Article illustration

By Sea

Provide seaport to seaport service

Suitable for goods over 100kg

Delivery: 2-45 days

Cost: low cost

Article illustration

4. Contact information

For more details, pls contact us freely.

Email address: Tina@fdachem.com

Mob: 86 13213167925

WhatsApp/Skype/Wechat/LINE: 86 13213167925

Company Profile Introduction

Henan Fengda Chemical Co., Ltd. is located in the High-tech Development Zone of Henan Province. Specializing in the production and sales of various fine chemical products required for industrial production, including chemical raw materials, organic raw materials, petrochemicals, chemical reagents, solvents, catalysts, and additives, etc.

Recommended supplier

Product name	Price		Suppliers	Update time
Atazanavir	$0.00/25KG	VIP5Y	Hebei Mojin Biotechnology Co., Ltd	2023-10-16
Atazanavir	$0.00/1KG	VIP2Y	Hebei Guanlang Biotechnology Co., Ltd.	2023-03-29
Atazanavir	$100.00/1KG		Shijiazhuang Gantuo Biotechnology Co., Ltd	2023-03-10
Atazanavir	$200.00/1kg		Hebei Mingeng Biotechnology Co., Ltd	2022-11-23
Atazanavir	$0.00/1Kg/Bag	VIP4Y	WUHAN FORTUNA CHEMICAL CO., LTD	2021-07-14
Atazanavir	$15.00/1KG		Zhuozhou Wenxi import and Export Co., Ltd	2021-07-10
Atazanavir	$1.00/1KG	VIP6Y	Career Henan Chemical Co	2018-08-20
Atazanavir	$15.00/1KG		Zhuozhou Wenxi import and Export Co., Ltd	2021-07-08
atazanavir	$15.00/1KG		Zhuozhou Wenxi import and Export Co., Ltd	2021-06-26